Skip to main content
Signal8
Launch Terminal

Pulmatrix, Inc. (PULM)

Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Pulmatrix, Inc. logo

Pulmatrix, Inc.

NASDAQ:PULMHealthcare
-1.06%$1.40
AH$1.40+0.00%vs close
Mkt Cap$5.11M
Float3.65M
O/S3.65M
Vol
$ Vol
RVOL
Inst Own9.1%
SI1.2%
Earnings
Dilution
Pulmatrix, Inc. logoNASDAQ:PULM$1.40-1.06%
Phase Distribution
15 lead-sponsored trials·0 active·12 completed
Phase 111
Phase 1/21
Phase 22
Not applicable1
(1 more as collaborator)
Status Overview
Completed12
Stopped3

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2
    Terminated

    Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

    PUR1900, Placebo

    Allergic Bronchopulmonary Aspergillosis

    Enrollment
    7
    Start
    Jul 2019
    Primary Completion
    Jul 2020
    Completion
    Jul 2020
    NCT03960606
  • Phase 2
    Terminated

    Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

    Itraconazole Powder, Placebo

    ABPA

    Enrollment
    8
    Start
    Feb 2023
    Primary Completion
    Feb 2024
    Completion
    Feb 2024
    NCT05667662
  • Phase 1/2
    Terminated

    A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60

    RUT058-60, Sterile saline for irrigation

    Postoperative Wound Infection-deep, Post Operative Wound Infection

    Enrollment
    9
    Start
    Oct 2014
    Primary Completion
    Jun 2015
    Completion
    Jun 2015
    NCT02280395
  • Phase 1
    Completed

    Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects

    PUR003, Placebo

    Healthy

    Enrollment
    24
    Start
    Jul 2009
    Primary Completion
    Sep 2009
    Completion
    Oct 2009
    NCT00947687
  • Phase 1
    Completed

    Effect of PUR003 on Asthma

    PUR003, Placebo

    Asthma, Lung Diseases +1

    Enrollment
    7
    Start
    Dec 2009
    Primary Completion
    Oct 2011
    Completion
    Oct 2011
    NCT00989521
  • Phase 1
    Completed

    Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118

    PUR118

    Chronic Obstructive Pulmonary Disease

    Enrollment
    90
    Start
    Feb 2011
    Primary Completion
    Jun 2012
    Completion
    Jun 2012
    NCT01333904
  • Phase 1
    Completed

    A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis

    PUR118

    Cystic Fibrosis

    Enrollment
    10
    Start
    Feb 2012
    Primary Completion
    Dec 2012
    Completion
    Dec 2012
    NCT01543191
  • Phase 1
    Completed

    Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers

    PUR118

    Chronic Obstructive Pulmonary Disease (COPD)

    Enrollment
    24
    Start
    Aug 2012
    Primary Completion
    Apr 2013
    Completion
    Apr 2013
    NCT01690949
  • Phase 1
    Completed

    A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients

    PUR0200, PUR0200 Placebo

    Chronic Obstructive Pulmonary Disease (COPD)

    Enrollment
    38
    Start
    Jul 2013
    Primary Completion
    Dec 2013
    Completion
    Dec 2013
    NCT01921712
  • Phase 1
    Completed

    21 Day Cumulative Skin Irritation of RUT058-60

    Hypochlorous acid solution 106 mg/L, 0.1% (w/v) Sodium Lauryl Sulfate

    Irritation/Irritant

    Enrollment
    43
    Start
    Jul 2014
    Primary Completion
    Aug 2014
    Completion
    Sep 2014
    NCT02198963
  • Phase 1
    Completed

    A PK Study to Evaluate PUR0200 and a Reference Product in Healthy Subjects

    PUR0200, Reference Product

    Healthy

    Enrollment
    42
    Start
    Jan 2016
    Primary Completion
    Mar 2016
    Completion
    Mar 2016
    NCT02671825
  • Phase 1
    Completed

    Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in Healthy Volunteers and Adults With Asthma

    Itraconazole Powder, Itraconazole 200 mg

    Asthma

    Enrollment
    58
    Start
    Feb 2018
    Primary Completion
    Jun 2018
    Completion
    Jun 2018
    NCT03479411
  • Phase 1
    Completed

    A Phase 1b Study of PUR1800 in Patients With COPD

    Placebo Comparator, PUR1800 250 ug

    Chronic Obstructive Pulmonary Disease (COPD)

    Enrollment
    18
    Start
    Jan 2021
    Primary Completion
    Dec 2021
    Completion
    Dec 2021
    NCT04759807
  • Phase 1
    Completed

    A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults

    PUR3100, Dihydroergotamine (D.H.E 45)

    Healthy

    Enrollment
    26
    Start
    Jun 2022
    Primary Completion
    Sep 2022
    Completion
    Sep 2022
    NCT05351086
  • Observational
    Completed

    Determination of the in Vitro Effects of Cationic Airway Lining Modulators (CALM) on Chronic Obstructive Pulmonary Disease (COPD) Sputum

    -

    Chronic Obstructive Pulmonary Disease

    Enrollment
    10
    Start
    Apr 2010
    Primary Completion
    Jun 2010
    Completion
    Oct 2010
    NCT01096173
Search ClinicalTrials.gov for “Pulmatrix”